Researchers at the University of Nottingham have developed a wearable wrist device designed to help people with Tourette’s syndrome manage their tics. Named Neupulse, the device uses peripheral nerve stimulation, delivering mild electrical pulses to the median nerve at the wrist to influence brain activity associated with movement control.

Tourette’s syndrome is a neurodevelopmental condition characterised by involuntary movements and vocalisations, known as tics. The condition typically develops during childhood and can vary in severity.

A clinical trial published in the Journal of Neuropsychology in 2023 examined the effects of rhythmic median nerve stimulation in 121 people with Tourette’s syndrome or persistent tic disorders. Participants who received active stimulation experienced an average reduction of more than 25 per cent in tic frequency. The study also reported improvements in tic severity following four weeks of treatment.

Device awaits medical regulatory approval

Developed by the University of Nottingham in collaboration with its spin-out company Neurotherapeutics Ltd, Neupulse has two versions. Neupulse-C is marketed as a consumer wellness device, while Neupulse-M is intended for use as a medical device specifically for treating tics and Tourette’s syndrome.

The medical version is awaiting regulatory approval. In its May 2025 assessment, the UK's National Institute for Health and Care Excellence (NICE) identified Neupulse as a promising technology but outlined the need for further evidence on its clinical effectiveness, long-term benefits and cost-effectiveness.

The technology is intended for people aged 12 and above, as well as adults. Further evidence generation will be necessary before its suitability for wider adoption within the NHS can be established.